Working… Menu

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03259425
Recruitment Status : Terminated (DSMC Recommendation)
First Posted : August 23, 2017
Results First Posted : October 10, 2019
Last Update Posted : November 3, 2020
Bristol-Myers Squibb
Takara Bio Inc.
Information provided by (Responsible Party):
University of Utah

Brief Summary:
This is a single-arm, open label, Phase II study evaluating the safety and efficacy of neoadjuvant Nivolumab and HF10 in resectable stage IIIB, IIIC, and IVM1a melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Nivolumab Drug: HF10 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a single-arm, open label, Phase II
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Actual Study Start Date : December 21, 2017
Actual Primary Completion Date : September 21, 2018
Actual Study Completion Date : September 25, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab and HF10, all patients Drug: Nivolumab
Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then patient will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
Other Name: OPDIVO

Drug: HF10
1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.

Primary Outcome Measures :
  1. Pathological Response [ Time Frame: 12 weeks ]
    Following 12 weeks of neoadjuvant treatment with nivolumab and HF10, patients underwent definitive surgery. A percent viable tumor was assessed semi-quantitatively in the definitive surgical resection specimen by estimating the proportion of residual tumor in relation to the total tumor area and reported as percentage viability. A pathologic complete response was defined as no viable residual melanoma cells in the surgical specimen. A major pathologic response was defined as <50% viable tumor cells. A minor pathologic response was defined as 50% or greater viable tumor cells, including specimens that had 100% viability at surgery.

Secondary Outcome Measures :
  1. Recurrence-free Survival [ Time Frame: 1 year post surgery ]
    Recurrence after surgery will be assessed by radiologic scans scheduled per section 8 and confirmed by biopsy.

  2. Overall Survival [ Time Frame: 2 years (1 year after stopping 1 year of Nivolumab) ]
    patients will be followed for survival for one year after completion of adjuvant nivolumab

  3. Complete Surgical Resection [ Time Frame: Within 28 days after Day 84 ]
    patients will be assessed at surgery to determine if complete surgical resection was achievable after neo-adjuvant treatment with nivolumab and HF10.

  4. Rate of Adverse Events for Patients While Taking Nivolumab and HF10 [ Time Frame: Patient safety will be evaluated throughout the treatment period and follow up (Treatment with HF10 is expected to last for 84 days, treatment with nivolumab is expected to last 1 year for each patient after surgery and follow up for 1 year ]
    patients will be monitored for adverse events related to nivolumab and HF10 using CTCAE criteria

  5. Radiographic Response Per RECIST 1.1 [ Time Frame: 12 weeks from baseline to surgery ]
    Patients will be assessed radiographically with CT or MRI scan or assessed clinically.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be >18 years or older.
  • Patients must have stage IIIB, IIIC, or IVM1a (equivalent staging at time of enrollment via American Joint Committee on Cancer (AJCC) 7th edition) metastatic melanoma which is eligible for complete surgical resection.
  • Prior systemic, regional and radiation anticancer therapies must have been completed at least three months prior to enrollment. Prior therapies (including anti-programmed death (PD)-1 inhibitors) are allowed provided three months have elapsed from last dose.
  • Patients must be a candidate for intralesional therapy.
  • At least 1 injectable cutaneous, subcutaneous, or nodal melanoma lesion > 10 mm in longest diameter OR
  • Multiple injectable melanoma lesions which in aggregate have a longest diameter of > 10 mm AND
  • Must have no known bleeding diathesis or coagulopathy that would make intratumoral injection unsafe.
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Serum (LDH) level < 1.5 upper limit of normal (ULN) within 28 days prior to enrollment.
  • Patients have adequate organ function within 28 days prior to enrollment, as defined in the protocol
  • Men and women of childbearing potential must agree to use adequate contraception from the time of consent through 7 months after final nivolumab study treatment.
  • Females of childbearing potential must have a negative urine or serum pregnancy test within 1 week prior to the start of treatment.
  • Patients must be able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

  • Patients with active visceral, central nervous system, or any bone metastases melanoma (Stage IVM1b or IVM1c).
  • Patients whose primary diagnosis was ocular melanoma.
  • Patients receiving anti-herpes medication (i.e., acyclovir, famciclovir, or valacyclovir) within 1 week prior to initiating HF10 treatment. Patients may not require intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug other than intermittent topical use.
  • Patients who have an active herpetic skin lesion(s) or prior complications of herpes simplex virus (HSV)-1 infection.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
  • Medical history of autoimmune disease (e.g. Crohn's disease, ulcerative colitis) or other disease requiring systemic glucocorticoid or immunosuppressive therapy. Subjects who receive daily steroid replacement therapy serve as an exception to this rule. Daily prednisone equivalent at doses up to 10 mg would qualify.
  • Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Epstein-Barr Virus (EBV) infection are excluded.
  • Pregnant or breast feeding women; women desiring to become pregnant within the timeframe of the study are also excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03259425

Layout table for location information
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
Bristol-Myers Squibb
Takara Bio Inc.
  Study Documents (Full-Text)

Documents provided by University of Utah:
Layout table for additonal information
Responsible Party: University of Utah Identifier: NCT03259425    
Other Study ID Numbers: HCI102346
First Posted: August 23, 2017    Key Record Dates
Results First Posted: October 10, 2019
Last Update Posted: November 3, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Utah:
Resectable Stage IIIB, IIIC, and IVM1a
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action